Features of ovarian cancer in Lynch syndrome (Review)

  • Authors:
    • Kanako Nakamura
    • Kouji Banno
    • Megumi Yanokura
    • Miho Iida
    • Masataka Adachi
    • Kenta Masuda
    • Arisa Ueki
    • Yusuke Kobayashi
    • Hiroyuki Nomura
    • Akira Hirasawa
    • Eiichiro Tominaga
    • Daisuke Aoki
  • View Affiliations

  • Published online on: August 20, 2014     https://doi.org/10.3892/mco.2014.397
  • Pages: 909-916
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9‑2.7%. Lynch syndrome accounts for 10‑15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65‑75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non‑serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3‑kinase/mammalian target of the rapamycin pathway and anti‑epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.
View References

Related Articles

Journal Cover

November-December 2014
Volume 2 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakamura K, Banno K, Yanokura M, Iida M, Adachi M, Masuda K, Ueki A, Kobayashi Y, Nomura H, Hirasawa A, Hirasawa A, et al: Features of ovarian cancer in Lynch syndrome (Review). Mol Clin Oncol 2: 909-916, 2014.
APA
Nakamura, K., Banno, K., Yanokura, M., Iida, M., Adachi, M., Masuda, K. ... Aoki, D. (2014). Features of ovarian cancer in Lynch syndrome (Review). Molecular and Clinical Oncology, 2, 909-916. https://doi.org/10.3892/mco.2014.397
MLA
Nakamura, K., Banno, K., Yanokura, M., Iida, M., Adachi, M., Masuda, K., Ueki, A., Kobayashi, Y., Nomura, H., Hirasawa, A., Tominaga, E., Aoki, D."Features of ovarian cancer in Lynch syndrome (Review)". Molecular and Clinical Oncology 2.6 (2014): 909-916.
Chicago
Nakamura, K., Banno, K., Yanokura, M., Iida, M., Adachi, M., Masuda, K., Ueki, A., Kobayashi, Y., Nomura, H., Hirasawa, A., Tominaga, E., Aoki, D."Features of ovarian cancer in Lynch syndrome (Review)". Molecular and Clinical Oncology 2, no. 6 (2014): 909-916. https://doi.org/10.3892/mco.2014.397